Rishi P. Singh, MD, and Michael A. Klufas, MD, provide an overview of the significance of and need for biosimilars in the ophthalmology space, and review the approval pathway for biosimilars.

Michael A. Klufas, MD, discusses the significance of interchangeability of biosimilars and being able to substitute biosimilars for reference products, as well as the path to achieving the designation of interchangeability from the FDA.

Expert retina specialists review the impact of biosimilars in clinical ophthalmology practice, highlighting the potential decrease of financial burden to the patient.

Michael A. Klufas, MD, discusses issues with off-label bevacizumab use, focusing on compounding issues and decreases in clinical efficacy due to repackaging.

Rishi P. Singh, MD; and Michael A. Klufas, MD, comment on the reasoning behind a shorter primary end point for biosimilar studies.

Rishi P. Singh, MD; and Michael A. Klufas, MD, provide an overview of the 2 currently available ophthalmology biosimilars, ranibizumab-eqrn and ranibizumab-nuna, as well as discuss which patient populations will benefit from these treatments.

Retina specialists review the current challenges with biosimilars in ophthalmology, commenting on insurance coverage and patient assistance programs.

Rishi P. Singh, MD; and Michael A. Klufas, MD, discuss how to gain both physician and patient trust when it comes to using biosimilars to treat ophthalmologic conditions.